News

Allurion Technologies Inc. (NYSE:ALUR) Q1 2025 Earnings Call Transcript May 14, 2025 Allurion Technologies Inc. beats earnings expectations. Reported EPS is $0.43, expectations were $-1.53.
Chardan Capital also issued estimates for Allurion Technologies’ FY2025 earnings at ($4.39) EPS. Separately, Roth Mkm reaffirmed a “buy” rating and issued […] Skip to main content ...
Good morning, and thank you all for joining us. Earlier today, Allurion Technologies Inc. issued a press release announcing financial results for the quarter ended December 31st, 2024 and provided ...
Allurion Technologies Inc. (ALUR) reported its Q4 2024 earnings, revealing a notable decline in revenue and gross profit compared to the previous year. Despite these challenges, the company outlined ...
Allurion Technologies Inc. (ALUR) reported its Q4 2024 earnings, revealing a notable decline in revenue and gross profit compared to the previous year. Despite these challenges, the company ...
The company plans to evaluate its Allurion Program with GLP-1 agonists to address muscle loss concerns and promote healthier weight loss. Allurion entered into a securities purchase agreement to ...
Allurion Technologies (ALUR) announced its intention to initiate a clinical study on the combination of the Allurion Program with GLP-1 agonists to improve muscle mass and overall body composition.
NATICK, Mass., December 24, 2024--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) ("Allurion" or the "Company"), a company dedicated to ending obesity ...
NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today ...
Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that its Board of Directors ...
Allurion Technologies, a weight loss platform, launched AllurionMeds to give patients GLP-1 medications for weight loss combined with its AI-enabled Coach Iris platform. The company aims to advance ...